Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 25 Mar 2020 2:39 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Gulf War Illness Research Program (GWIRP) to support research addressing Gulf War Illness (GWI) pathobiology, diagnosis, and treatment. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The FY20 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    Applications submitted to the FY20 GWIRP must address one or more of the following Overarching Challenges:

    Treatments: Eliminate the health consequences associated with GWI and revolutionize treatment

    Diagnosis: Better define and diagnose GWI

    Subtyping: Distinguish symptom clusters to better target treatments, identify underlying causes, and elucidate differences in severity

    Determinants: Validate exposures associated with GWI and impacts on organs and systems

    Consequences: Determine whether GWI is associated with greater risk for developing other disease states including neurological diseases, cancers, or other life-threatening and severely debilitating conditions

    Communicate: Help veterans, their caregivers, researchers and health care providers communicate effectively about GWI, its symptoms, and potential treatments

    https://cdmrp.army.mil/funding/gwirp

    Idea Award – Preproposal due May 29, 2020

    Independent investigators at all academic levels

    · Supports innovative, high-risk/high-reward research in the earliest stages of development that will contribute to markers or treatments for Gulf War Illness (GWI).

    · Emphasis is on impact and innovation; applications must articulate how results will lead to a clinical impact for Veterans with GWI, even if a clinical impact is not an immediate outcome.

    · Preliminary data not required.

    · Clinical trials not allowed.

    · Submission of a pre-application is required; application submission is by invitation only.

    · Biorepository Contribution Option:

    · Supports additional costs associated with submission of samples and data to the GWIRP-supported Boston Biorepository, Recruitment, and Integrative Network

    · Applicants must submit a Biorepository Contribution Statement providing a detailed accounting of proposed costs and a commitment to work with the GWIRP-supported Biorepository Resource Network.

    · Application to this option is not a requirement for Idea Award submission.

    · Maximum funding of $150,000 for direct costs (plus indirect costs)

    · Maximum funding of $170,000 for direct costs with the Biorepository Contribution Option (plus indirect costs).

    · Maximum period of performance is 2 years

    Research Advancement Award – Preproposal due May 29, 2020

    Independent investigators at all academic levels

    · Supports applied research in GWI that is aimed at continued expansion and validation of markers and treatments that are supported by evidence in the GWI field.

    · Preliminary data in field of GWI and other supporting information are required.

    · Applications must articulate how results will lead to a clinical impact for Veterans with GWI, even if a clinical impact is not an immediate outcome.

    · Clinical trials not allowed.

    · Submission of a pre-application is required; application submission is by invitation only.

    · Biorepository Contribution Option:

    · Supports additional costs associated with submission of samples and data to the GWIRP supported Biorepository Resource Network.

    · Applicants must submit a Biorepository Contribution Statement providing a detailed accounting of proposed costs and a commitment to work with the GWIRP-supported Biorepository Resource Network.

    · Application to this option is not a requirement for Research Advancement Award submission.

    · Maximum funding of $625,000 for direct costs (plus indirect costs)

    · Maximum funding of $645,000 for direct with the Biorepository Contribution Option (plus indirect costs).

    · Maximum period of performance is 3 years

    Clinical Evaluation Award – Preproposal due May 29, 2020

    Independent investigators at all academic levels

    · Supports translational of validated GWI research, including qualified and replicated preclinical findings, to a Gulf War Veteran population.

    · Statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints or proof-of-concept intervention trials (e.g., pilot, first in human, Phase I-IIa) are encouraged under this funding opportunity.

    · Preliminary data are required.

    · Funding for this award mechanism must support research in a Gulf War Veteran population. Proof of availability and access to necessary cohort(s) and/or critical reagents must be provided.

    · Submission of a pre-application is required; application submission is by invitation only.

    Biorepository Contribution Option:

    · Supports additional costs associated with submission of samples and data to the GWIRP-supported Biorepository Resource Network.

    · Applicants must submit a Biorepository Contribution Statement providing a detailed accounting of proposed costs and a commitment to work with the GWIRP-supported Biorepository Resource Network.

    · Application to this option is not a requirement for Clinical Evaluation Award submission.

    Clinical Consortium Collaboration Option:

    Supports additional costs associated with collaboration with the GWIRP- supported Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC).

    Applicants must submit a Clinical Consortium Collaboration Statement providing a detailed accounting of proposed costs and clearly articulating the qualifications of the research team and institution to participate as a new Clinical Research Site in the Consortium.

    Application to this option is not a requirement for Clinical Evaluation Award submission.

    · Maximum funding of $1,500,000 for direct costs (plus indirect costs).

    · Maximum funding of $1,520,000 for direct costs with the Biorepository Contribution Option (plus indirect costs).

    · Maximum funding of $1,700,000 for direct costs with the Clinical Consortium Collaboration Option (plus indirect costs).

    · Maximum period of performance is 3 years

    Therapeutic/Biomarker Trial Award – Preproposal due May 29, 2020

    Independent investigators at all academic levels

    · Supports large-scale, pivotal (Phase IIb or III) trials that revolutionize the clinical management of GWI.

    · Proposed research should lead to an approach that is fundamentally better than interventions already approved or in clinical development.

    · Objective biomarkers to measure the biological effect of an investigational therapeutic or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual Gulf War Veteran or Gulf War Veteran subgroup must be included in the trial design.

    · Investigators must have experience in successfully leading large-scale projects and demonstrated the ability to implement a clinical project successfully.

    · Funding must be used to support a clinical trial.

    · Preproposal submission is required; application submission is by invitation only.

    · Biorepository Contribution Option:

    · Supports additional costs associated with submission of samples and data to the GWIRP-supported Biorepository Resource Network

    · Application must submit a Biorepository Contribution Statement providing a detailed accounting of proposed costs and a commitment to work with the GWIRP=supported Biorepository Resource Network.

    · Application to this option is not a requirement for Therapeutic/Biomarker Trial Award submission.

    · Clinical Consortium Collaboration Option:

    · Supports additional costs associated with collaboration with the GWIRP-supported Gulf War Illness Clinical Trials and Interventions Consortium

    · Applicants must submit a Clinical Consortium Collaboration Statement providing a detailed accounting of proposed costs and clearly articulates the qualifications of the research tea and institution to participate as a new Clinical Research Site in the Consortium.

    · Application to this option is not a requirement for Therapeutic/Biomarker Trial Award submission.

    · Funding must be used to support a clinical trial.

    · Maximum funding of $5,000,000 for direct costs (plus indirect costs)

    · Maximum funding of $5,020,000 for direct costs with the Biorepository Contribution Option (plus indirect costs).

    · Maximum funding of $5,500,000 for direct costs with the Clinical Consortium Collaboration Option (plus indirect costs).

    · Maximum period of performance is 4 years

    Patient-Provider and Health Communications Award – Preproposal due May 29, 2020

    Independent investigators at all academic levels

    · Supports projects aimed at tools and processes to raise awareness of GWI research and clinical findings within communities, including Veterans with GWI and/or their caregivers or advocates, healthcare providers who serve Veterans with GWI, or public health professional relevant to Veterans with GWI.

    · Maintenance and sustainment of the dissemination effort past the award period for continued awareness of GWI research and clinical findings to diverse audiences is an important review criterion.

    · Must include a description of evaluation metrics and tracking to assist in measuring the success of the communication tool process.

    · Must include at least one consumer GWI advocate, who will be integral throughout the planning and implementation of the research project.

    · Clinical trials not allowed.

    · Preproposal submission is required; application submission is by invitation only.

    · Maximum funding of $600,000 for direct costs (plus indirect costs)

    · Maximum period of performance is 3 years

    New Investigator Award – Preproposal due May 29, 2020

    Investigators may apply under one of the following three eligibility categories:

    Transitioning Postdoctoral Fellow: Senior postdoctoral fellows with at least 3 years of postdoctoral training

    Early-Career Investigator:Independent investigators within 5 years since their last training position

    New GWI Researcher: Established independent investigators who have received less than $300,000 in federally funded, non-mentored GWI research

    · Encourages applications from early-stage and established investigators new to the field of GWI research.

    · Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers are strongly encouraged.

    · Preliminary data not required.

    · Clinical trials not allowed.

    · Preproposal submission is required; application submission is by invitation only.

    · Biorepository Contribution Option:

    · Supports additional costs associated with submission of samples and data to the GWIRP-supported Biorepository Resource Network.

    · Applicants must submit a Biorepository Contribution Statement providing a detailed accounting of proposed costs and a commitment to work with the GWIRP-supported Biorepository Resource Network.

    · Application to this option is not a requirement for New Investigator Award submission.

    · Maximum funding of $500,000 for direct costs (plus indirect costs)

    · Maximum funding of $520,000 for direct costs with the Biorepository Contribution Option (plus indirect costs)

    · The maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Point of Contact:

    CDMRP Help Desk

    301-682-5507

    help@eBrap.org


  • 23 Mar 2020 9:21 AM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides $40 million (M) to the Department of Defense Spinal Cord Injury Research Program (SCIRP) to support innovative, high-impact spinal cord injury (SCI) research1.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

     

    The FY20 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

     

    Applications submitted to the FY20 SCIRP must address one or more of the following focus areas:

     

    • Preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
    • Identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies (Translational Research Award and Investigator-Initiated Research Award only)
    • Bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain
    • Psychosocial issues relevant to people with SCI, their families, and/or their care partners

    Rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing

    • neuroplasticity and recovery to improve function after SCI

     

    https://cdmrp.army.mil/funding/scirp

     

    Clinical Trial Award – Preproposal due May 21, 2020

    Investigators at all academic levels (or equivalent)

    ·         Preproposal is required; application submission is by invitation only.

    ·         Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of SCI.

    ·         Applications must include at least two individuals with lived SCI experience as members of the research team.

    ·         Preclinical data required for all clinical trial applications.

    ·         Maximum funding of $3M for direct costs (plus indirect costs)

    ·         Maximum period of performance is years

     

    Translational Research Award – Preproposal due May 21, 2020

    Investigators at all academic levels (or equivalent)

    ·         Preproposal is required; application submission is by invitation only.

    ·         Fund translational research studies that accelerate the movement of promising ideas in SCI research into clinical applications.

    ·         Applications must include at least one individual with lived SCI experience as a member of the research team.

    ·         The SCIRP TRA may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.

    ·         Preliminary data required.

    ·         Maximum funding of $1.25M for direct costs (plus indirect costs)

    ·         Maximum period of performance is 3 years

     

    Investigator-Initiated Research Award – Preproposal due May 21, 2020

    Investigators at all academic levels (or equivalent)

    ·         Preproposal is required; application submission is by invitation only.

    ·         Fund and phase of SCI-related research from basic through translational that has the potential to make an important contribution to SCI research, patient care, and/or quality of life.

    ·         Clinical trials not allowed.

    ·         Preliminary data required.

    ·       Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·       Maximum period of performance is 3 years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 20 Mar 2020 11:37 AM | Hawk Tran (Administrator)

    On March 9, 2020, OMB issued M-20-11, "Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly impacted by the Novel Coronavirus (COVID-19)," to provide agencies with additional flexibilities for grants assisting the response to COVID-19. The scope of the M-20-11 was narrowly crafted to provide flexibility to grant recipients performing essential research and services necessary to carry out the emergency response related to COVID-19.

    Please click this link to read the memo put out by OMB concerning guidance on administrative relief: https://www.whitehouse.gov/wp-content/uploads/2020/03/M-20-17.pdf
  • 20 Mar 2020 10:57 AM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Kidney Cancer Research Program (KCRP) to support research of exceptional scientific merit in the area of kidney cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity.  This pre-announcement should not be construed as an obligation by the Government.  The FY20 KCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website.  Pre-application and application deadlines will be available when the Program Announcements are released. 

    Applications submitted to the FY20 KCRP Idea Development Award mechanism are encouraged to address one or more of the following Areas of Emphasis:

    ·        Treatments/Survivorship

    • Noninvasive Interventions
    • Surgical Interventions
    • Therapeutic Development
    • Understanding and Managing Toxicity
    • Survivorship and Patient Experience

    ·        Basic/Translational Science

    • Genetics
    • Chromatin and Gene Regulation
    • Metabolism
    • Microenvironment and Immunology
    • Environmental Exposures (and/or Deployment-Related Exposures)
    • New Disease Model Systems
    • Rare Kidney Cancers
    • Mechanism of Response and Resistance

    ·        Diagnostics/Prognostics/Biomarkers/Surveillance

    • Prognosis
    • Biomarker Development
    • Novel Imaging Technologies
    • Liquid Biopsy
    • Microbiome
    • Disease Disparities

    ·        Population-Based Studies

    • Screening and Early Detection
    • Surveillance
    • Outcome/Population-Based Studies
    • Environmental Exposures (and/or Deployment-Related Exposures)
    • Disease Disparities

    https://cdmrp.army.mil/pubs/press/2020/20kcrppreann

    Academy of Kidney Cancer Investigators – Early-Career Investigator Award

    Within 3 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline

    Letter attesting to eligibility required

    ·      Supports addition of new Early-Career Investigators (ECIs) to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty

    ·      ECIs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply

    ·      Requires Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding

    ·      Designated Mentor not required to be at the same institution as the ECI

    ·      Preliminary data required

    ·      Clinical trials allowed

    ·      Submission of a Letter of Intent required prior to full application submission

    ·     Maximum funding of $725,000 for direct costs (plus indirect costs)

    ·     Maximum period of performance 4 years

    Clinical Consortium Award Clinical Trial Site

    Independent Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Supports expansion of a consortium that will facilitate rapid execution of collaborative Phase II or Phase I/II clinical trials to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease impact of kidney cancer

    ·      Funds may not be used for research or development of clinical protocols

    ·      Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged

    ·      Up to two (2) Clinical Trial Sites will be selected and be jointly responsible for proposing, selecting, and conducting trials within the existing Kidney Cancer Research Consortium

    ·      Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer

    ·      Submission of a Letter of Intent required prior to full application submission

    Clinical Trial Sites:

    ·     Maximum funding of $600,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance 3 years

    Clinical Trial Nurse Training Award New for FY20

    As of full application submission deadline, Principal Investigators must possess an RN, Bachelor’s, Master’s, or Doctoral degree in nursing

    ·      Prepares nurses for active careers in collaborative clinical kidney cancer research and patient care

    ·      Requires participation of a mentor with extensive experience in kidney cancer clinical research

    ·      Emphasis placed on structured, interdisciplinary clinical research training environment

    ·      Submission of a Letter of Intent required prior to full application submission

    ·     Maximum funding of $300,000 for direct costs (plus indirect costs)

    ·     Maximum period of performance 2 years

    Concept Award

    Investigators at all academic levels

    ·      Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer

    ·      Emphasis on innovation

    ·      Funding for clinical trials not allowed

    ·      Preliminary data not allowed

    ·      Blinded review

    ·      Submission of a Letter of Intent required prior to full application submission

    ·     Maximum funding of $100,000 for direct costs (plus indirect costs)

    ·     Maximum period of performance 1 year

    Idea Development Award  Modified for FY20

    Established Investigators: 

    Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree

    Early Career Investigators:

    Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline

    ·      Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer

    ·      Preliminary data required

    ·      Innovation and Impact are the most important review criteria

    ·      Funding for clinical trials not allowed

    ·      FY20 KCRP Areas of Emphasis strongly encouraged (see Areas of Emphasis listed above)

    ·      Different funding options, based on the scope of research.  It is the responsibility of the PI to select the funding option that is most appropriate for the research proposed. 

    ·      Early Detection Option:  Supports basic or preclinical research that focuses on biomarkers, improved imaging capabilities, and/or new technologies that may foster new paradigms for the early detection of kidney cancer.  With justification, applications under the early detection option may request a higher level of funding within the defined period of performance.  Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.

    ·      Epidemiology Option:  Supports preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the kidney cancer field.  With compelling justification, epidemiology option studies may request higher levels of funding within the defined period of performance.  Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens

    ·      Submission of a Letter of Intent is required prior to full application submission.

    ·      Maximum funding of $600,000 in direct costs (plus indirect costs)

    ·      Maximum period of performance 3 years

    Early Detection Option:

    ·      Maximum funding of $650,000 in direct costs (plus indirect costs)

    ·      Maximum period of performance 3 years

    Epidemiology Option:

    ·      Maximum funding of $2 million in direct costs (plus indirect costs)

    ·      Maximum period of performance 3 years

    Postdoctoral and Clinical Fellow Award New for FY20

    As of full application submission deadline, Principal Investigators:

    • Must possess a doctoral and/or medical degree (or equivalent).
    • Have 3 years or less of postdoctoral and/or mentored clinical research training experience (excluding family medical leave)
    • All other academic ranks are ineligible.

    ·      Supports research opportunities focused on kidney cancer for individual in the early stages of their careers

    ·      Requires participation of a designated mentor who is an experienced kidney cancer researcher

    ·      Submission of a Letter of Intent required prior to full application submission

    ·      Maximum funding of $195,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance 3 years

    Translational Research Partnership Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications

    ·      Supports translational correlative studies

    ·      Preliminary data required

    ·      Funding for clinical trials not allowed

    ·      Submission of a Letter of Intent required prior to full application submission

    ·      Maximum funding of $750,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website(https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 19 Mar 2020 12:08 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Hearing Restoration Research Program (HRRP) to support promising, necessary research for treatment of burdensome and very prevalent auditory system injury.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The HRRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity.  This pre-announcement should not be construed as an obligation by the Government.  The FY20 HRRP Program Announcement and General Application Instructions for the following award mechanism will be posted on the Grants.gov website.  Pre-application and application deadlines will be available when the Program Announcement are released. 

    Applications submitted to the FY20 HRRP must address one or more of the following Focus Areas:

    • Accelerate translation of biological regeneration/repair mechanisms into therapies that treat auditory system injury and restore auditory function.  For example, but not limited to:
    • o   Hair cell regeneration/repair/recovery
    • o   Neural regeneration/repair/recovery
    • o   Treatment for synaptopathy and hidden hearing loss
    • Diagnostic tests that help differentiate sensory, neural, synaptic, and central processing disorders, that may inform applicability and outcomes for current or future hearing restoration therapeutics.
    • Develop reliable in-vitro human models to facilitate the understanding, derivation and characterization of human auditory cells, and/or to facilitate the evaluation of hearing restoration therapies.
    • Develop and/or validate techniques/methods beyond the audiogram to diagnose acute auditory system injury in austere or remote environments.  For example, but not limited to, simple and rapid assessments that are compatible with portable platforms.
    • Preproposal is required; application submission is by invitation only.
    • Funding Level 1 supports exploratory, high-risk/high-reward research in the earliest stages of development.
    • Research must have the potential to yield new avenues of investigation, such as new approaches, new research tools, or new paradigms.
    • While preliminary data is not required, applicants must provide solid rationale of the research idea. 
    • The investigating team must have sufficient expertise to test the idea.
    • Funding Level 2 supports the advancement of more mature research that has the potential to make significant advancements toward clinical translation.
    • Preliminary data supporting the readiness and feasibility of the proposed research is required.
    • May include, as a portion of the proposed research, a pilot clinical trial component that collects preliminary data to inform the feasibility, rationale, and design of subsequent clinical trials. 
    • The PI is responsible for selecting the funding level most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • Tinnitus or vestibular-related research is excluded.

    Funding Level 1:

    ·        Maximum funding of $250,000 for direct costs (plus indirect costs)

    ·        The maximum period of performance is years.

    Funding Level 2:

    ·        Maximum funding of $1M for direct costs (plus indirect costs)

    ·        The maximum period of performance is years.

    Funding Level 2 with Pilot Clinical Trial Option:

    ·        Maximum funding of $1.25M for direct costs (plus indirect costs)

    ·        The maximum period of performance is years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the HRRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 18 Mar 2020 1:41 PM | Hawk Tran (Administrator)

    Gray & Associates have released a synopsis concerning the on-going developments in Congress to control the spread of COVID-19. Please refer to this document here. It can also be found in the "Links and Documents" section on the NAVREF COVID-19 Response Page.

  • 18 Mar 2020 9:56 AM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $10 million to the Department of Defense Military Burn Research Program (MBRP) to support a research portfolio in the treatment of burns and the trauma associated with burn injuries sustained during combat or combat-related activities. Outcomes of successful research are anticipated to benefit Service members, Veterans, and the general public.  The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The FY20 MBRP Program Announcement and General Application Instructions for the following award mechanism are posted on the Grants.gov website.

    The MBRP encourages applications that propose research that advances the development or refinement of interventions, technologies, or knowledge projects that will enable non-medical personnel or medical first responders to provide appropriate burn care closer to the point of injury to enhance the potential for better long-term outcomes. Applications submitted to the FY20 MBRP must address at least one of the following Focus Areas:   

    • Burn care solutions for use by non-medical first responders in a Prolonged Field Care (PFC) scenario.
    • Burn care solutions for use by the medical first responder in the pre-hospital setting (not necessarily in a PFC scenario).

    https://cdmrp.army.mil/funding/mbrp

    Clinical Translational Research Award – Preproposal due May 15, 2020

    Independent investigators at all academic levels (or equivalent)

    • Supports clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, pre-clinical, or clinical research findings to the care of the burn-injured patient.
    • The proposed study must include clinical research, and may include initial proof of concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
    • Large randomized clinical trials are discouraged.
    • Preliminary data is required.
    • Animal research is not allowed.
    • Pre-application is required; application submission is by invitation only.
    • Maximum funding of $1.5 million (M) for total costs (direct costs plus indirect costs)
    • Maximum period of performance is 4 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 17 Mar 2020 11:45 AM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The FY20 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    Applications submitted to the FY20 LCRP must address one or more of the following Areas of Emphasis:

    *Identify innovative strategies for the screening and early detection of lung cancer.

    *Understand the molecular mechanisms of initiation and progression to lung cancer.

    *Identify innovative strategies for prevention of the occurrence of lung cancer.

    *Identify innovative strategies for the treatment of lung cancer.

    *Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.

    *Develop or optimize prognostic or predictive markers to assist with therapeutic decision-making.

    *Understand mechanisms of resistance to treatment (primary and secondary).

    *Understand contributors to lung cancer development other than tobacco.

    *Identify innovative strategies for lung cancer care delivery (disparities/clinical management/ surveillance/symptom management).

    Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY20 LCRP during programmatic review.   Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

    *Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research

    *Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators

    *Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population

    *Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

    https://cdmrp.army.mil/funding/lcrp

    Concept Award – Letter of Intent due May 27, 2020

    Investigators at all academic levels

    • Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.
    • Emphasis on innovation.
    • Clinical trials not allowed.
    • Preliminary data discouraged.
    • Relevance to military health strongly encouraged.
    • Maximum funding of $100,000 in direct costs (plus indirect costs).
    • Period of performance should not exceed 1 year.

    Idea Development Award – Preproposal due May 6, 2020

    Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or

    New Investigators:  Investigators that meet the following criteria by the application submission deadline date:

    • Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award
    • Are within 10 years of first faculty appointment (or equivalent)
    • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
    • Emphasis on innovation and impact.
    • New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
    • Clinical trials not allowed.
    • Preliminary data required.
    • Relevance to military health strongly encouraged.
    • Maximum funding of $350,000 in direct costs (plus indirect costs).
    • Period of performance should not exceed 2 years.

    Investigator-Initiated Translational Research Award - Preproposal due May 6, 2020

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    *Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.

    • This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:
    • Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts
    • Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug submission
    • Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials
    • Preliminary data required.
    • Relevance to military health strongly encouraged.
    • Maximum funding of $400,000 in direct costs (plus indirect costs).
    • Period of performance should not exceed 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website.

    Point of Contact:

    CDMRP Help Desk

    301-682-5507

    help@eBrap.org


  • 17 Mar 2020 9:09 AM | Hawk Tran (Administrator)

    The Office of Research and Development (ORD) is pleased to announce a webinar scheduled for Thursday, March 19th, from 2:30-4:00pm EST.  Details can be found below:

    • Topic:  ORD Research Response to COVID-19
    • Date: Thursday, March 19th, 2020 
    • Time: 2:30 – 4:00pm EST
    • Purpose:  The purpose of this training is to provide an update on VA’s Office of Research and Development organizational and research activities in response to COVID-19.  The presenters will discuss strategies for handling research-related activities in the context of COVID-19 in the VA.
    • Presenters:
      • Rachel Ramoni, DMD, ScD – Chief Research and Development Officer (CRADO)
      • Wendy Tenhula, PhD – Deputy CRADO
      • Grant Huang, MPH, PhD – Deputy CRADO, Enterprise Optimization (Acting)
      • Molly Klote, MD – Director, Office of Research Protections, Policy and Education
    • Target Audience:  Research committee members, research office staff, compliance officers, and Investigator and study team members.
    • Software Requirements:  Be sure you have Adobe Flash installed on your computer We suggest you log on using chrome.
    • Recording:  This training will be recorded

    Please distribute this announcement within your facility to others who may benefit from this training. 

     

    You can find registration information for future ORPP&E training opportunities as well as recordings of past webinars on our cyberseminar webpage:   https://www.research.va.gov/programs/orppe/education/webinars/default.cfm

    Handouts will be sent out the morning of the scheduled training.

     

    Please email vhacoordregulatory@va.gov if you would like to be added to our training notification listserv.


  • 11 Mar 2020 12:51 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $3 million (M) to the Department of Defense Bone Marrow Failure Research Program (BMFRP) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on BMF diseases. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The FY20 BMFRP Program Announcement and General Application Instructions for the following award mechanism are posted on the Grants.gov website.

    https://cdmrp.army.mil/funding/bmfrp

    Idea Development Award – Preproposal due date May 11, 2020

    Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from first faculty appointment (or equivalent) at the time of the application submission or

    Early Career Investigators:
    Independent investigators at the level of Assistant Professor (or equivalent) and less than 10 years from his/her first faculty appointment (or equivalent) at the time of application submission deadline are eligible.

    • Pre-application is required; full application submission is by invitation only.
    • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure bone marrow failure (BMF).
    • Proposed research should have a high probability of revealing new avenues of investigation.
    • Research project should include well-formulated, testable hypothesis and a well-developed and articulated research approach.
    • Strong BMF research team.
    • May include relevant preliminary data.
    • Clinical trials will not be supported.
    • The maximum allowable funding for the entire period of performance is $325,000 in direct costs (plus indirect costs).
    • The maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software